Daliresp (roflumilast) – Package leaflet - R03DX07

Updated on site: 06-Oct-2017

Medication nameDaliresp
ATC CodeR03DX07
ManufacturerAstraZeneca AB

Package leaflet: Information for the patient

Daliresp 500 micrograms film-coated tablets


This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

-Keep this leaflet. You may need to read it again.

-If you have any further questions, ask your doctor or pharmacist.

-This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.

-If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet:

1.What Daliresp is and what it is used for

2.What you need to know before you take Daliresp

3.How to take Daliresp

4.Possible side effects

5.How to store Daliresp

6.Contents of the pack and other information

1 What Daliresp is and what it is used for

Daliresp contains the active substance roflumilast, which is an anti-inflammatory medicine called phosphodiesterase-4 inhibitor. Roflumilast reduces the activity of phosphodiesterase-4, a protein occurring naturally in body cells. When the activity of this protein is reduced, there is less inflammation in the lungs. This helps to stop narrowing of airways occurring in chronic obstructive pulmonary disease (COPD). Thus Daliresp eases breathing problems.

Daliresp is used for maintenance treatment of severe COPD in adults who in the past had frequent worsening of their COPD symptoms (so-called exacerbations) and who have chronic bronchitis. COPD is a chronic disease of the lungs that results in tightening of the airways (obstruction) and swelling and irritation of the walls of the small air passages (inflammation). This leads to symptoms such as coughing, wheezing, chest tightness or difficulty in breathing. Daliresp is to be used in addition to bronchodilators.

2 What you need to know before you take Daliresp

Do not take Daliresp

-if you are allergic to roflumilast or any of the other ingredients of this medicine (listed in section 6)

-if you have moderate or severe liver problems.

Warnings and precautions

Talk to your doctor or pharmacist before taking Daliresp

Sudden attack of breathlessness

Daliresp is not intended for the treatment of a sudden attack of breathlessness (acute bronchospasms). In order to relieve a sudden attack of breathlessness it is very important that your doctor provides you with another medicine to be available to you at all times that can cope with such an attack. Daliresp will not help you in this situation.

Body weight

You should check your body weight on a regular basis. Talk to your doctor if, while taking this medicine, you observe an unintentional loss of body weight (not related to a diet or exercise programme).

Other diseases

Daliresp is not recommended if you have one or more of the following diseases:

-severe immunological diseases such as HIV infection, multiple sclerosis (MS), lupus erythematosus (LE) or progressive multifocal leukoencephalopathy (PML)

-severe acute infectious diseases such as tuberculosis, or acute hepatitis

-cancer (except basal-cell carcinoma, a slow-growing type of skin cancer)

-or severe impairment of the heart function

There is a lack of relevant experience with Daliresp under these conditions. You should talk to your doctor, if you are diagnosed with any of these diseases.

Experience is also limited in patients with a previous diagnosis of tuberculosis, viral hepatitis, herpes viral infection or herpes zoster. Please talk to your doctor if you have one of these diseases.

Symptoms you should be aware of

You may experience diarrhoea, nausea, abdominal pain or headache during the first weeks of treatment with Daliresp. Talk to your doctor if these side effects do not resolve within the first weeks of treatment.

Daliresp is not recommended in patients with a history of depression associated with suicidal thinking or behaviour. You may also experience sleeplessness, anxiety, nervousness, or depressive mood. Before starting treatment with Daliresp, inform your doctor if you are suffering from any symptoms of this kind and of any additional medicines you may take since some of those could increase the probability of these side effects. You or your caregiver should also immediately inform your doctor of any changes in behaviour or mood and of any suicidal thoughts you may have.

Children and adolescents

Daliresp should not be used by children and adolescents under 18 years of age.

Other medicines and Daliresp

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, especially the following:

-a medicine containing theophylline (a medicine to treat respiratory diseases), or

-a medicine used for treatment of immunological diseases, such as methotrexate, azathioprine, infliximab, etanercept, or oral corticosteroids to be taken long-term.

-a medicine containing fluvoxamine (a medicine to treat anxiety disorders and depression), enoxacin (a medicine to treat bacterial infections) or cimetidine (a medicine to treat stomach ulcers or heartburn).

The effect of Daliresp may be reduced if taken together with rifampicin (an antibiotic medicine) or with phenobarbital, carbamazepine or phenytoin (medicines usually prescribed for the treatment of epilepsy). Ask your doctor for advice.

Daliresp may be taken with other medicines used in the treatment of COPD such as inhaled or oral corticosteroids or bronchodilators. Do not stop taking these medicines or reduce their dose unless advised by your doctor.

Pregnancy and breast-feeding

Do not take Daliresp if you are or plan to become pregnant, think you may be pregnant, or are breast-feeding. You should not become pregnant during treatment with this medicine and should use an effective method of contraception during therapy, because Daliresp may be harmful for the unborn baby.

Driving and using machines

Daliresp has no influence on the ability to drive and use machines.

Daliresp contains Lactose

If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.

3 How to take Daliresp

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

The recommended dose is one 500 micrograms tablet once daily.

Swallow the tablet with some water. You may take this medicine with or without food. Take the tablet at the same time every day.

You may need to take Daliresp for several weeks to achieve its beneficial effect.

If you take more Daliresp than you should

If you have taken more tablets than you should, you may experience the following symptoms: headache, nausea, diarrhoea, dizziness, throbbing of your heart, light-headedness, clamminess and low blood pressure. Tell your doctor or pharmacist straight away. If possible take your medicine and this leaflet with you.

If you forget to take Daliresp

If you forget to take a tablet at the usual time, take the tablet as soon as you remember on the same day. If on one day you have forgotten to take a tablet of Daliresp, just carry on the next day with the next tablet as usual. Continue taking your medicine at the usual times. Do not take a double dose to make up for a forgotten dose.

If you stop taking Daliresp

It is important to continue taking Daliresp for as long as prescribed by your doctor, even when you have no symptoms, in order to maintain control of your lung function.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4.Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

You may experience diarrhoea, nausea, stomach ache or headache during the first weeks of treatment with Daliresp. Talk to your doctor if these side effects do not resolve within the first weeks of treatment.

Some side effects could be serious. In clinical studies and post-marketing experience, rare instances of suicidal thinking and behaviour (including suicide) were reported. Please notify your doctor immediately

of any suicidal thoughts you may have. You may also experience sleeplessness (common), anxiety (uncommon), nervousness (rare), panic attack (rare) or depressive mood (rare).

In uncommon cases allergic reactions may occur. Allergic reactions may affect the skin and in rare cases cause swelling of the eyelids, face, lips and tongue, possibly leading to difficulties in breathing and/or a drop in blood pressure and accelerated heartbeat. In case of an allergic reaction, stop taking Daliresp and contact your doctor immediately, or go immediately to the emergency department in the nearest hospital. Take all your medicines and this leaflet with you and provide full information of your current medications.

Other side effects include the following:

Common side effects (may affect up to 1 in 10 people)

-diarrhoea, nausea, stomach ache

-weight decrease, decreased appetite


Uncommon side effects (may affect up to 1 in 100 people)

-trembling, sensation of spinning head (vertigo), dizziness

-sensation of rapid or irregular heartbeat (palpitations)

-gastritis, vomiting

-reflux of stomach acid to the gullet (acid regurgitations), indigestion


-muscle pain, muscle weakness or cramps

-back pain

-feeling of weakness or tiredness, feeling unwell.

Rare side effects (may affect up to 1 in 1,000 people)

-male breast enlargement

-decreased sense of taste

-respiratory tract infections (excluding pneumonia)

-bloody stools, constipation

-elevation of liver or muscle enzymes (seen in blood tests)

-wheals (urticaria).

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5.How to store Daliresp

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.

This medicine does not require any special storage conditions.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Daliresp contains

-The active substance is roflumilast. Each film-coated tablet (tablet) contains 500 micrograms roflumilast.

-The other ingredients are:

-Core: lactose monohydrate, maize starch, povidone (K90), magnesium stearate,

-Coating: hypromellose, Macrogol 4000, titanium dioxide (E171), and iron oxide yellow (E172).

What Daliresp looks like and contents of the pack

Daliresp 500 micrograms film-coated tablets are yellow, D-shaped film-coated tablets, embossed with 'D' on one side.

Each pack contains 10, 30, or 90 film-coated tablets. Not all pack sizes may be marketed.

Marketing Authorisation Holder

AstraZeneca AB

SE-151 85 Södertälje



Takeda GmbH

Production site Oranienburg Lehnitzstraße 70-98

16515 Oranienburg Germany

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:



AstraZeneca S.A./N.V.

UAB AstraZeneca Lietuva

Tel: +32 2 370 48 11

Tel: +370 5 2660550



АстраЗенека България ЕООД

AstraZeneca S.A./N.V.

Тел.: +359 24455000

Tél/Tel: +32 2 370 48 11

Česká republika


AstraZeneca Czech Republic s.r.o.

AstraZeneca Kft.

Tel: +420 222 807 111

Tel.: +36 1 883 6500



AstraZeneca A/S

Associated Drug Co. Ltd

Tlf: +45 43 66 64 62

Tel: +356 2277 8000



AstraZeneca GmbH

AstraZeneca BV

Tel: +49 41 03 7080

Tel: +31 79 363 2222




AstraZeneca AS

Tel: +372 6549 600

Tlf: +47 21 00 64 00



AstraZeneca A.E.

AstraZeneca Österreich GmbH

Τηλ: +30 210 6871500

Tel: +43 1 711 31 0



Laboratorio Tau, S.A.

AstraZeneca Pharma Poland Sp. z o.o.

Tel: +34 91 301 91 00

Tel.: +48 22 245 73 00




AstraZeneca Produtos Farmacêuticos, Lda.

Tél: +33 1 41 29 40 00

Tel: +351 21 434 61 00



AstraZeneca d.o.o.

AstraZeneca Pharma SRL

Tel: +385 1 4628 000

Tel: +40 21 317 60 41



AstraZeneca Pharmaceuticals (Ireland) Ltd

AstraZeneca UK Limited

Tel: +353 1609 7100

Tel: +386 1 51 35 600


Slovenská republika

Vistor hf.

AstraZeneca AB, o.z.

Sími: +354 535 7000

Tel: +421 2 5737 7777



Simesa S.p.A.

AstraZeneca Oy

Tel: +39 02 9801 1

Puh/Tel: +358 10 23 010



Αλέκτωρ Φαρµακευτική Λτδ

AstraZeneca AB

Τηλ: +357 22490305

Tel: +46 8 553 26 000


United Kingdom

SIA AstraZeneca Latvija

AstraZeneca UK Ltd

Tel: +371 67377100

Tel: +44 1582 836 836

This leaflet was last approved in

Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu


  • Help
  • Get it on Google Play
  • About
  • Info on site by:

  • Presented by RXed.eu

  • 27558

    prescription drugs listed